Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
insulin glargine (Abasaglar®)
Reference No. 2307
Publication date:
10/12/2015
Appraisal information
insulin glargine (Abasaglar®) 100 units/ml solution for injection
Company:
Eli Lilly & Co Ltd
BNF category:
Endocrine system
NMG meeting date:
07/10/2015
AWMSG meeting date:
11/11/2015
Submission Type:
Full Submission
Status:
Recommended with restrictions
Advice No:
3215
Ratification by Welsh Government:
09/12/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Insulin glargine (Abasaglar®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Insulin glargine (Abasaglar®) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus®), the reference product. Insulin glargine (Abasaglar®) is not recommended for use within NHS Wales outside of these circumstances. Insulin glargine (Abasaglar®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Final Appraisal Recommendation (FAR)
Download
insulin glargine (Abasaglar) 2307 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
insulin glargine (Abasaglar) 2307 ASAR
Clinical Expert (CE) Summary
Download
insulin glargine (Abasaglar) 2307 CE Summary